OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome

Matteo Balzarro; Emanuele Rubilotta; Andrea Braga; Silvia Bassi; Tania Processali; Walter Artibani; Maurizio Serati

doi:10.1016/j.ejogrb.2018.05.002

OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome

Eur J Obstet Gynecol Reprod Biol. 2018 Jun:225:228-231. doi: 10.1016/j.ejogrb.2018.05.002. Epub 2018 May 5.

Authors

Matteo Balzarro¹, Emanuele Rubilotta², Andrea Braga³, Silvia Bassi², Tania Processali², Walter Artibani², Maurizio Serati⁴

Affiliations

¹ Dept. of Urology Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale Aristide Stefani 1, Verona, 37126, Italy. Electronic address: matteo.balzarro@aovr.veneto.it.
² Dept. of Urology Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale Aristide Stefani 1, Verona, 37126, Italy.
³ Dept. of Dept. of Obstetrics and Gynecology, EOC - Beata Vergine Hospital, via Turconi 23, Mendrisio, 6850, Switzerland.
⁴ Dept. of Obstetrics and Gynecology, University of Insubria, via Ravasi 2, Varese, 21100, Italy.

PMID: 29753213
DOI: 10.1016/j.ejogrb.2018.05.002

Abstract

Objectives: The correlation between changes in sexual function and improvements in LUTD in patients treated with OnabotulinumtoxinA (onaBoNT-A) detrusor injection is unclear and limited only to women with neurogenic OAB. The aim of this study was to evaluate the impact of OnabotulinumtoxinA (onaBoNT-A) injection on sexual function in women undergoing this treatment for idiopathic wet overactive bladder (OAB).

Study design: This is a pilot three-center observational study including women affected by idiopathic wet overactive bladder refractory to standard conservative treatments and underwent onaBoNT-A injection. Sexuality was assessed using the Female Sexual Function Index (FSFI). A 3-day voiding diary, OAB screener questionnaire (OAB-S), and the international consultation on incontinence questionnaire short form (ICIQ-sf) were completed before and 3 months after onaBoNT-A injection to evaluate OAB symptoms.

Results: All the 32 enrolled patients were included for statistical analysis. These patients received 100U of onaBoNT-A. Significant improvement of many FSFI domains was found. Only desire and pain domains had no significant improvements. The FSFI total score showed a significant improvement (P 0.0008). Clinical efficacy has been documented by voiding diaries, OAB-S scores, and ICIQ-sf scores. Correlation between UUI episodes and FSFI total score was statistically significant (r = -0.73; p = 0.04) while no significant correlation was found between the number of micturition and FSFI total score.

Conclusion: Women who underwent successful OnaBoNT-A detrusor injection to treat wet OAB, showed an improvement in sexual function due to the significant correlation between the improvement of urinary urge incontinence and a better gratification of sexuality.

Keywords: Female sexual dysfunction; OnabotulinumtoxinA; Overactive bladder.

Publication types

Multicenter Study
Observational Study

MeSH terms

Acetylcholine Release Inhibitors / administration & dosage
Acetylcholine Release Inhibitors / therapeutic use*
Adult
Aged
Botulinum Toxins, Type A / administration & dosage
Botulinum Toxins, Type A / therapeutic use*
Female
Humans
Injections, Intralesional
Middle Aged
Pilot Projects
Quality of Life
Sexual Dysfunction, Physiological / drug therapy*
Sexual Dysfunction, Physiological / etiology
Treatment Outcome
Urinary Bladder / drug effects
Urinary Bladder, Overactive / complications
Urinary Bladder, Overactive / drug therapy*
Urination / drug effects

Substances

Acetylcholine Release Inhibitors
Botulinum Toxins, Type A